Related Experiment Video

Updated: Jul 4, 2026

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
10:52

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System

Published on: December 10, 2021

Re: Autopsy-proven Huntington's disease with 29 trinucleotide repeats

Alicia Semaka, Simon Warby, Blair R Leavitt

    Movement Disorders : Official Journal of the Movement Disorder Society
    |June 13, 2008
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
    07:08

    Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

    Published on: February 27, 2018

    Measuring RAN Peptide Toxicity in C. elegans
    10:49

    Measuring RAN Peptide Toxicity in C. elegans

    Published on: April 30, 2020

    Related Experiment Videos

    Last Updated: Jul 4, 2026

    Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
    10:52

    Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System

    Published on: December 10, 2021

    Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
    07:08

    Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

    Published on: February 27, 2018

    Measuring RAN Peptide Toxicity in C. elegans
    10:49

    Measuring RAN Peptide Toxicity in C. elegans

    Published on: April 30, 2020

    Related Concept Videos

    Huntington Disease l: Introduction01:21

    Huntington Disease l: Introduction

    Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...

    Articles linked to this work by shared authors, journal, and citation graph.

    Design and development of lipid nanoparticle formulations for brain gene therapy.

    Molecular therapy. Nucleic acids·2026

    Classical and Emerging Biomarkers in Pyridoxine-Dependent Epilepsy (PDE-ALDH7A1): Implications for Early Diagnosis and Therapeutic Development.

    Biomolecules·2026

    Humanized mice carrying a pathogenic GRN deletion as a pre-clinical platform for targeted gene therapies in frontotemporal dementia.

    Neurobiology of disease·2026

    Wild-type huntingtin in neurodevelopment.

    Journal of Huntington's disease·2026

    Silencing of human HTT by targeted CRISPR/dCas9-mediated epigenetic editing.

    Journal of Huntington's disease·2026

    Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial.

    Nature medicine·2026

    The Costs of Parkinson's Disease in Europe: Results of the Costs of Illness in Neurology Initiative.

    Movement disorders : official journal of the Movement Disorder Society·2026

    Decoding Sleep Architecture from Ambulatory Basal Ganglia Signals in Parkinson's Disease.

    Movement disorders : official journal of the Movement Disorder Society·2026

    Phase 2a Randomized Controlled Trial of TPN-101, A Nucleoside Reverse Transcriptase Inhibitor, in Progressive Supranuclear Palsy.

    Movement disorders : official journal of the Movement Disorder Society·2026

    Integrative Multi-Omics Analysis Reveals Convergent Epigenome and Transcriptome Changes in Parkinson's Disease.

    Movement disorders : official journal of the Movement Disorder Society·2026

    Evolution of Epidemiological Studies in Movement Disorders.

    Movement disorders : official journal of the Movement Disorder Society·2026

    Apathy in Lewy Body Disorders: A Position Paper.

    Movement disorders : official journal of the Movement Disorder Society·2026

    Targeting glycine transporter type 1 (GlyT1) in epilepsy: Pathophysiological rationale and therapeutic perspectives.

    Pharmacology & therapeutics·2026

    [Autism - Phenotypic variability].

    Medicina·2026

    Significant differences in phenotype and age of onset in an SPG4 family caused by whole SPAST deletion combined with a hemizygous S44L modifier.

    Neurogenetics·2026

    A Novel Mutation in ACTG1 as the Probable Cause of Nonsyndromic Hearing Loss in Chinese Han Population.

    Neural plasticity·2026

    Rare missense variants in NECTIN1 alter local protein structure and may contribute to non-syndromic cleft lip with or without palate.

    Frontiers in genetics·2026

    Two Novel Compound Heterozygous CDH23 Mutations Underlying Non-Syndromic Hearing Loss.

    International journal of general medicine·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us